Although osimertinib and afatinib have anti‐tumor efficacy against EGFR L861R‐positive lung adenocarcinoma, we should investigate the efficacy of EGFR‐TKIs in EGFR L861 mutation‐positive cases using a large number of cases. Here, EGFR is linked to lung adenocarcinoma.